Pharmaessentia Corporation

Christoph Klade

Ko-Chung Lin

Oleh Zagrijtschuk

Described is a method for treating an infectious disease, cancer, or myeloproliferative disease in a subject, wherein a 50 to 540 μg dose of a pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Dosage regimen for pegylated interferon

A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 &#x3bc;g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Growing community of inventors

Vienna, Austria

Christoph Klade